CM
CGON icon

Crestline Management’s CG Oncology CGON Stock Holding History

Crestline Management’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-95,439
Closed -$2.74M – 112
2024
Q4 		$2.74M Buy
95,439
+87,549
+1,110% +$3M 0.09% 228
2024
Q3 		$298K Buy
+7,890
New +$277K 0.02% 457

Other funds holding CGON

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return

Crestline Management's CGON Position: Q1 2025 in Review

Crestline Management sold out of CG Oncology (CGON) in Q1 2025, closing a stake of 95,439 shares — an estimated $2.74M sold.

Crestline Management first reported a position in CGON in Q3 2024 and held it in 2 quarters. The position peaked at $2.74M in Q4 2024. 142 funds tracked by Wall St. Rank hold CGON as of Q1 2025.

  • Crestline Management reported no remaining CG Oncology position as of Q1 2025 after selling out during the quarter.
  • Crestline Management sold 95,439 CG Oncology shares in Q1 2025, an estimated $2.74M.
  • Crestline Management first reported a position in CG Oncology in Q3 2024 and held it in 2 quarters.
  • Crestline Management's CG Oncology position peaked at $2.74M in Q4 2024.
  • 142 funds tracked by Wall St. Rank held CG Oncology as of Q1 2025.

Based on Crestline Management's 13F filing for Q1 2025, filed 15 May 2025.